Potential Action Mechanism of Erianin in Relieving MNNG-triggered Chronic Atrophic Gastritis

Overview

Journal Cell Biochem Biophys

Specialties Biochemistry
Biophysics
Cell Biology

Date 2024 Sep 19

PMID 39298066

Authors

Qianqian Jiang

Guoxia Fan

Kaiwei Wu

Affiliations

Soon will be listed here.

Abstract

Chronic atrophic gastritis (CAG) is a critical initial step in gastric cancer tumorigenesis accompanied by high malignancy. Erianin has been proposed as a promising agent in treating precancerous lesions of gastric cancer. Considering that little work has been implemented concerning the specific role and possible regulatory mechanism of Erianin in CAG, the goal of the study is to disclose the effects and mechanism of erianin on the malignant transformation in the process of CAG. CAG cell model was generated in human gastric epithelium GES-1 cells induced by Nmethyl-N'-nitro-N-nitrosoguanidine (MNNG). CCK-8 method determined cell viability. ELISA and corresponding assay kits severally appraised the contents of inflammatory cytokines and oxidative stress markers. Cellular reactive oxygen species (ROS) formation was measured by flow cytometry analysis using DCFH-DA probe. GFP-LC3 immunofluorescence staining and Western blotting evaluated autophagy. Also, Western blotting analyzed the expression of components in mitogen activated protein kinase (MAPK)/mechanistic target of rapamycin (mTOR) signaling. The results manifested that MNNG treatment diminished the viability and autophagy whereas intensified the inflammation and oxidative stress in GES-1 cells, which were all reversed by Erianin. Besides, Erianin blocked mTOR/MAPK signaling in MNNG-exposed GES-1 cells. Autophagy inhibitor 3-methyladenine (3-MA) or p38 MAPK agonist asiatic acid partially counteracted the protection elicited by Erianin against viability loss, inflammatory reaction as well as oxidative stress in MNNG-induced GES-1 cells. Combined with the findings, Erianin might mediate autophagy to improve MNNG-elicited CAG via MAPK/mTOR signaling.

References

Luo C, Sun Z, Li Z, Zheng L, Zhu X . Notoginsenoside R1 (NGR1) Attenuates Chronic Atrophic Gastritis in Rats. Med Sci Monit. 2019; 25:1177-1186. PMC: 6381808. DOI: 10.12659/MSM.911512. View

Lahner E, Conti L, Annibale B, Corleto V . Current Perspectives in Atrophic Gastritis. Curr Gastroenterol Rep. 2020; 22(8):38. DOI: 10.1007/s11894-020-00775-1. View

Smyth E, Nilsson M, Grabsch H, van Grieken N, Lordick F . Gastric cancer. Lancet. 2020; 396(10251):635-648. DOI: 10.1016/S0140-6736(20)31288-5. View

Yang L, Liu X, Zhu J, Zhang X, Li Y, Chen J . Progress in traditional Chinese medicine against chronic gastritis: From chronic non-atrophic gastritis to gastric precancerous lesions. Heliyon. 2023; 9(6):e16764. PMC: 10258419. DOI: 10.1016/j.heliyon.2023.e16764. View

Liu X, Wang S, Li J, Zhang J, Liu D . Regulatory effect of traditional Chinese medicines on signaling pathways of process from chronic atrophic gastritis to gastric cancer. Chin Herb Med. 2022; 14(1):5-19. PMC: 9476726. DOI: 10.1016/j.chmed.2021.10.008. View

Wang Y . Traditional uses, chemical constituents, pharmacological activities, and toxicological effects of Dendrobium leaves: A review. J Ethnopharmacol. 2021; 270:113851. DOI: 10.1016/j.jep.2021.113851. View

Li G, Zhang H, Lai H, Liang G, Huang J, Zhao F . Erianin: A phytoestrogen with therapeutic potential. Front Pharmacol. 2023; 14:1197056. PMC: 10440559. DOI: 10.3389/fphar.2023.1197056. View

Zhang Y, Zhang Q, Wei F, Liu N . Progressive study of effects of erianin on anticancer activity. Onco Targets Ther. 2019; 12:5457-5465. PMC: 6628150. DOI: 10.2147/OTT.S200161. View

Wang Y, Chu F, Lin J, Li Y, Johnson N, Zhang J . Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental.... J Ethnopharmacol. 2021; 279:114399. DOI: 10.1016/j.jep.2021.114399. View

10.

Gaestel M . MAPK-Activated Protein Kinases (MKs): Novel Insights and Challenges. Front Cell Dev Biol. 2016; 3:88. PMC: 4705221. DOI: 10.3389/fcell.2015.00088. View

11.

Saxton R, Sabatini D . mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017; 168(6):960-976. PMC: 5394987. DOI: 10.1016/j.cell.2017.02.004. View

12.

Zhang Q, Wang X, Cao S, Sun Y, He X, Jiang B . Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways. Biomed Pharmacother. 2020; 128:110245. DOI: 10.1016/j.biopha.2020.110245. View

13.

Wang K, Tang J, Fan S, Su H, Yu R, Zhang Y . ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K/AKT/mTOR/p70S6k and MAPK signaling pathways. Neoplasia. 2023; 45:100936. PMC: 10539879. DOI: 10.1016/j.neo.2023.100936. View

14.

Yang L, Liu Y, Gu Y, Guo Q . Deltonin enhances gastric carcinoma cell apoptosis and chemosensitivity to cisplatin inhibiting PI3K/AKT/mTOR and MAPK signaling. World J Gastrointest Oncol. 2023; 15(10):1739-1755. PMC: 10631430. DOI: 10.4251/wjgo.v15.i10.1739. View

15.

Yang L, Hu Y, Zhou G, Chen Q, Song Z . Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways. Biosci Rep. 2020; 40(7). PMC: 7385585. DOI: 10.1042/BSR20193137. View

16.

Zhang H, Xie X, Li G, Chen J, Li M, Xu X . Erianin inhibits human lung cancer cell growth via PI3K/Akt/mTOR pathway in vitro and in vivo. Phytother Res. 2021; 35(8):4511-4525. DOI: 10.1002/ptr.7154. View

17.

Tong Y, Liu L, Wang R, Yang T, Wen J, Wei S . Berberine Attenuates Chronic Atrophic Gastritis Induced by MNNG and Its Potential Mechanism. Front Pharmacol. 2021; 12:644638. PMC: 8026873. DOI: 10.3389/fphar.2021.644638. View

18.

Gushgari A, Halden R . Critical review of major sources of human exposure to N-nitrosamines. Chemosphere. 2018; 210:1124-1136. DOI: 10.1016/j.chemosphere.2018.07.098. View

19.

Lu L, Chen B, Zhang X, Xu Y, Jin L, Qian H . The effect of phytochemicals in N-methyl-N-nitro-N-nitroguanidine promoting the occurrence and development of gastric cancer. Front Pharmacol. 2023; 14:1203265. PMC: 10339287. DOI: 10.3389/fphar.2023.1203265. View

20.

Wen J, Tong Y, Ma X, Wang R, Li R, Song H . Therapeutic effects and potential mechanism of dehydroevodiamine on N-methyl-N'-nitro-N-nitrosoguanidine-induced chronic atrophic gastritis. Phytomedicine. 2021; 91:153619. DOI: 10.1016/j.phymed.2021.153619. View